Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition

International Journal of Clinical Pharmacology and Therapeutics

Volumn 40, Issue 1, 2002, Pages 9-17

  Cawello, W ^a   Boekens, H ^a   Waitzinger, J ^a   Miller, U ^a  

^a Schwarz Pharma AG   (Germany)

Author keywords

ACE inhibition; Food interaction; Lipophilicity; Moexipril; Moexiprilat; Pharmacokinetic pharmacodynamic modeling

Indexed keywords

BENAZEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; FOSINOPRIL; LISINOPRIL; MOEXIPRIL; MOEXIPRILAT; QUINAPRIL; RAMIPRIL; SPIRAPRIL; TRANDOLAPRIL;

ADULT; AGED; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SENSITIVITY; ENZYME INHIBITION; FOOD DRUG INTERACTION; FOOD INTAKE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; LIPOPHILICITY; MALE; NORMAL HUMAN; PHARMACODYNAMICS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL;

EID: 0036151677     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP40009     Document Type: Article

References (26)

1. Effect of ramipril an mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
2. Moexipril. A review of its use in the management of essential hypertension
3. The correlation between pharmacodynamics and pharmacokinetics: Basics of pharmacokinetics-pharmacodynamics modeling
4. Parameter for compartment-free pharmacokinetics
5. Compared properties of trandolapril, enalapril, and their diacid metabolites
6. Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor
7. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study
8. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: Pharmacological characterization and comparison with enalapril
9. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: Development of a mathematical model
10. Pharmacological and toxicological studies of the new angiotensin-converting enzyme inhibitor moexipril hydrochloride
11. Pharmacokinetic and pharmacodynamic data analysis: Concepts and Applications
12. Simultaneous determination of moexipril and moexiprilat, its active metabolite, in human plasma by gas chromatography-negative-ion chemical ionization mass spectrometry
13. Randomized trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity. The Swedish trial in old patients with hypertension-2 study
14. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial
15. Choosing the right ACE inhibitor
16. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
17. A study of the efficacy and safety of moexipril in mild to moderate hypertension
18. A double-blind evaluation of moexipril versus hydrochlorothiazide in hypertension
19. Safety and tolerance of single oral doses of trandolapril (RU 44.570), a new angiotensin-converting enzyme inhibitor
20. Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor compared to hydrochlorothiazide in elderly patients
21. Pharmacology and clinical use of the new ACE-inhibitor moexipril
22. Pharmacokinetics and ACE-inhibition of the new ACE-inhibitor moexipril: Is co-administration with food of clinical relevance?
23. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
24. Tricenter assessment of the efficacy of the ACE inhibitor moexipril by ambulatory blood pressure monitoring
25. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin-converting enzyme inhibitor (HOE 498) in healthy subjects